Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2003

View Archived Issues

BMS researchers describe two series of antidiabetic compounds

Novel immunosuppressants covered by Sankyo patent

Potent, selective PDE5 inhibitors prepared and tested at Lilly Icos

Agouron discovers novel nonpeptide GnRH antagonists

GSK scientists describe the discovery of novel anti-HCV agents

New antibacterial PDF inhibitors in early development at GSK

Pierre Fabre presents novel inhibitors of protein prenyltransferases

New data on cantuzumab mertansine in tumors expressing the CanAg antigen

Approval recommended for Enteryx in GERD

E.U. approves Taxotere in combination with cisplatin for first-line NSCLC treatment

CYC-202 enters phase IIa trials in breast and lung cancers

LidoPAIN IND cleared

ANDROMEDA trial discontinued due to safety concerns

Dosing begins in phase II trial of FM-VP4

Medarex and Abbott enter therapeutic antibody collaboration

Kiadis and U. of Bristol form neuropathic pain alliance

Applied Molecular Evolution completes preclinical validation of lead candidates

Potential use of nicotinic receptor antagonists as mood stabilizers in affective disorders

Hepacare marketing authorization withdrawn in E.U.

Disappointing phase II results reported for ReN-1869

HMR-1556 potently and selectively blocks the slowly activating delayed rectifier K+ current

Antimalarial activity of cyproheptadine involves inhibition of heme polymerization

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...